Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$3.44
+0.05 (+1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $221.3M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
8.8x
↓EV/EBITDA
5.7x
↓ROE
18.2%
↑Gross Margin
76.0%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.7%
FCF CAGR
-32.7%
FCF margin
8.3%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $943.3M · net income $251.2M · FCF $78.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $943.3M | $943.3M | $1.19B | $961.4M | $992.0M |
| Net Income | $251.2M | $251.2M | $318.6M | $250.2M | $281.2M |
| EBITDA | $377.1M | $377.1M | $489.1M | $410.8M | $424.9M |
| EPS | — | — | 0.43 | 0.34 | 0.38 |
| Gross Margin | 76.0% | 76.0% | 75.5% | 72.6% | 72.7% |
| Operating Margin | 33.5% | 33.5% | 36.2% | 36.4% | 37.1% |
| Net Margin | 26.6% | 26.6% | 26.9% | 26.0% | 28.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.29 | 0.27 | 0.18 |
| Current Ratio | 2.17 | 2.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $78.0M | $78.0M | $408.6M | $221.3M | $255.3M |
| Returns | |||||
| ROE | 18.2% | 18.2% | 21.7% | 16.1% | 18.3% |
| Valuation | |||||
| P/E | 8.82 | 8.82 | 7.35 | 10.02 | 5.15 |
| EV/EBITDA | 5.73 | 5.73 | 3.35 | 4.59 | 1.94 |
| P/B | 1.85 | 1.85 | 1.60 | 1.62 | 0.94 |
| Growth & Yield | |||||
| Revenue Growth | -20.4% | -20.4% | 23.3% | -3.1% | — |
| EPS Growth | — | — | 27.4% | -11.0% | — |
| Dividend Yield | 10.0% | 10.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.43 → n/d
Residual
-34.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.